Basel-based BioMedPartners has announced the first closing of BioMedInvest II, the firm’s second venture capital fund, at CHF95m.
Basel-based BioMedPartners has announced the first closing of BioMedInvest II, the firm’s second venture capital fund, at CHF95m.
BioMedInvest II is a healthcare-dedicated fund that invests in early- to mid-stage companies in Switzerland, Germany and neighbouring countries of the European Union.
BioMedPartners, founded in 2003, has raised over CHF240m until today.
The new fund will invest in private human healthcare companies in Europe.
BioMedPartners says these companies offer significant return potential, as large pharma companies are increasingly acquiring biotech firms to fill their product pipelines.
The fund is backed by both existing and new investors, including the experienced lead investor ERP-EIF Dachfonds.
The fund will remain open for additional new investors for some months.
‘Up to now, BioMedPartners have invested in more than 25 companies and created a track record of successful exits through IPOs and trade sales, including the trade sale of Glycart Biotechnology AG to Roche. The overwhelming support and enthusiasm of existing and new investors validates the excellent and unique investment approach of BioMedPartners’, says Prof. Dr. Andrea Pfeifer, chairman of BioMedInvest I.
‘The fact that BioMedPartners were able to raise a new early stage fund in such turbulent times encourages the management team to continue with its favourable business model by investing in promising early stage healthcare companies in Europe and by actively supporting companies in their business/corporate development. BioMedPartners will strive to build a portfolio of mature companies and to generate successful exits and, hence, superior return for investors.’
